What Qtern Treats: Main Uses and Benefits

Qtern is a therapeutic agent generally used in the management of Type 2 diabetes mellitus to support the management of metabolic stability in the condition. The medication is generally applied as an adjunct to diet and exercise to assist with the management of blood sugar levels.

---

Managing Chronic High Blood Sugar and Long-Term Glycaemic Goals

This domain addresses the primary condition and the need for sustained glucose control. The medication is commonly used in conditions marked by chronic hyperglycemia (high blood sugar) and persistently elevated HbA1c levels. It assists with easing the overall metabolic burden by contributing to the consistent lowering of both fasting and postprandial glucose readings. A central therapeutic role involves assisting with improved glycaemic control, which helps support the patient during episodes of systemic imbalance and contributes to easing the overall symptom load for patients managing the condition.

---

Support for Inadequate Control on Monotherapy

This domain covers the specific clinical scenario where the patient's condition is not adequately controlled by a single antidiabetic agent, even with lifestyle modifications. Qtern, as a combination product, is relevant in settings where complex metabolic defects may require additional support in symptom management. The practical benefit for the patient is treatment simplification, as the fixed-dose format may reduce the pill burden and assists with maintaining functional stability within the long-term management regimen.

---

Quick Fact: Relief for Glucose Fluctuations Qtern is relevant for managing the symptomatic patterns associated with both elevated fasting and postprandial blood sugar levels, which create functional strain on the body.

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Who Can and Cannot Use Qtern?

Eligibility for Qtern is strictly defined by official regulatory labeling, setting clear boundaries for patient use.

Contraindicated Populations

Qtern is contraindicated and must not be used by patients who have a history of a serious hypersensitivity reaction to either dapagliflozin or saxagliptin, or any other Dipeptidyl Peptidase-4 (DPP-4) inhibitor. The medicine is also contraindicated in patients with:

• Moderate to severe renal impairment (estimated Glomerular Filtration Rate, or eGFR, < 45 mL/min/1.73m^2)
• End-Stage Renal Disease (ESRD) or those receiving dialysis
• Type 1 diabetes mellitus or diabetic ketoacidosis

Eligibility and Restriction Status

Category	Official Regulatory Status/Statement
Populations Allowed	Adults (age ge 18 years) with Type 2 diabetes mellitus.
Renal Function Threshold	Do not initiate if eGFR is below 60 mL/min/1.73m^2; discontinue if eGFR persistently falls below 45 mL/min/1.73m^2.
Age-Group Rules	Not recommended for children and adolescents (under 18 years) as safety and efficacy are not established.
Hepatic Impairment	Not recommended for use in patients with severe hepatic impairment.
Pregnancy/Lactation	Not recommended during the second and third trimesters of pregnancy or when breastfeeding.

Connection to the overall eligibility profile: Official regulatory documents classify the eligible population for Qtern as adults with Type 2 diabetes who meet specific clinical criteria. Eligibility is primarily restricted by the absolute contraindications related to serious allergic history and severe renal function impairment, ensuring non-use in populations where the medicine's safety and efficacy are not established or are prohibited.

Interactions with other medicines and products

Qtern's official interaction profile is structured around both pharmacokinetic (drug exposure) and pharmacodynamic (drug effect) considerations involving its two active components, Dapagliflozin and Saxagliptin.

Contraindicated and Exposure-Altering Combinations

Co-administration with strong Cytochrome P450 3A4/5 (CYP3A4/5) inhibitors, such as Ketoconazole or Ritonavir, is formally prohibited due to their potential to significantly increase the plasma concentrations ( AUC and C max) of the Saxagliptin component. Conversely, strong CYP3A4/5 inducers may decrease Saxagliptin exposure.

Pharmacodynamic and Procedural Constraints

Additive pharmacodynamic effects are documented when Qtern is used with other specific agent classes. Co-administration with Insulin or Insulin Secretagogues (e.g., Sulfonylureas) is associated with an increased risk of hypoglycemia. When combined with Diuretics, there is an officially noted additive risk of volume depletion or hypotension. Regarding procedures, Qtern should be withheld for at least 3 days, if possible, prior to major surgery or procedures associated with prolonged fasting.

Population-Specific Notes

Use in patients with severe hepatic impairment is not recommended, as exposure to both Dapagliflozin and Saxagliptin is documented to be increased in this population. Qtern is also contraindicated for improving glycemic control in patients with an estimated Glomerular Filtration Rate ( eGFR) below 45 mL/min/1.73 m^2.

Qtern is a fixed-dose combination product containing two active components, dapagliflozin and saxagliptin, that modulate distinct biological pathways to influence glucose metabolism.

Dapagliflozin functions as a selective inhibitor of the Sodium-Glucose Co-transporter 2 (SGLT2) protein, which is primarily located in the proximal renal tubules. By blocking SGLT2, dapagliflozin prevents the reabsorption of filtered glucose from the tubular lumen back into the systemic circulation. This action lowers the renal threshold for glucose and promotes the excretion of glucose via the urine (glucosuria), resulting in a net decrease in plasma glucose concentration.

Saxagliptin is a selective Dipeptidyl Peptidase-4 (DPP-4) enzyme inhibitor. The DPP-4 enzyme is responsible for the rapid inactivation of endogenous incretin hormones, such as Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP). Inhibition of DPP-4 elevates the circulating, active concentrations of these incretins. Increased GLP-1 and GIP activity leads to a glucose-dependent increase in insulin secretion from pancreatic beta cells and a concurrent decrease in glucagon secretion from pancreatic alpha cells. The combination of these two complementary mechanisms results in modulated glucose handling across the kidney and the pancreatic-gastrointestinal axis.

Qtern is administered orally as a film-coated tablet, typically following a once-daily schedule as part of a long-term treatment plan. The medicine is provided as a fixed-dose combination of dapagliflozin and saxagliptin, available in two strengths: 5 mg/5 mg and 10 mg/5 mg.

The standard regimen involves taking one tablet per day. The recommended maintenance dose is the 10 mg/5 mg strength. The tablet may be taken with or without food. While morning dosing is frequently suggested, the dose may be taken at any time of the day. Proper administration requires the tablet to be swallowed whole; it should not be crushed, cut, or chewed.

Usage of Qtern is subject to specific procedural constraints. The treatment should not be initiated if the patient's estimated Glomerular Filtration Rate (eGFR) is below 60 mL/min/1.73 m^2, and continued use requires kidney function to remain above this threshold. For severe hepatic impairment, use of the medicine is not recommended.

To ensure consistent dosing, specific guidance exists for missed doses to prevent doubling. Furthermore, therapy must be temporarily withheld for at least 3 days prior to major surgery or procedures associated with prolonged fasting.

Qtern: Recent Clinical Evidence

Qtern, which is a fixed-dose combination of the agents saxagliptin (a DPP-4 inhibitor) and dapagliflozin (an SGLT2 inhibitor), has been studied primarily in adults with Type 2 Diabetes Mellitus (T2DM) to evaluate its effect on blood glucose control.

---

Efficacy in Glycemic Control

The approval of Qtern was based on Phase III clinical trials evaluating the combination therapy as an add-on to metformin (a common first-line diabetes medication). These studies compared the combination tablet to the individual components plus metformin.

Trial Group	Mean Reduction in HbA1c (Approx.)	Key Observation
Saxagliptin/Dapagliflozin + Metformin	1.5 percentage points	Achieved the greatest reduction in HbA1c (a marker of long-term blood glucose).
Individual Agent + Metformin (Saxagliptin or Dapagliflozin)	0.9–1.2 percentage points	Reductions were less pronounced compared to the combination therapy.

In these randomized, double-blind trials, the combination resulted in a statistically greater reduction in glycated hemoglobin (HbA1c) from a starting average of approximately 9%, compared to either single agent when both were added to metformin. The trials also reported associated reductions in fasting plasma glucose (FPG) and body weight.

---

Safety and Special Populations

Safety data, generally pooled from studies involving both agents, indicated that the combined use was associated with adverse events characteristic of SGLT2 and DPP-4 inhibitors, such as urinary tract infections and genital mycotic infections.

Long-term data regarding cardiovascular (CV) safety is primarily derived from studies of the individual components, particularly dapagliflozin. Clinical trials are ongoing to explore the use and safety profile of the individual components in pediatric patients (aged 10 to 18) with T2DM, although Qtern itself is not indicated for this population.

Key Studies & References Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old (NCT03199053)

Common questions about Qtern (FAQ)

---

Q: What is Qtern used for?

A: Qtern is a combination prescription medicine containing saxagliptin and dapagliflozin. It is used along with diet and exercise to help improve blood sugar control in adults with Type 2 diabetes mellitus. This medication is not for treating Type 1 diabetes or diabetic ketoacidosis.

---

Q: How does Qtern work to lower blood sugar?

A: Qtern combines two different mechanisms. Dapagliflozin works by helping the kidneys remove glucose from the body. Saxagliptin works by increasing the levels of certain natural substances in the body that signal the pancreas to release more insulin when blood sugar levels are high.

---

Q: Does Qtern help with weight loss?

A: Some clinical studies suggested that dapagliflozin, one of the components of Qtern, was associated with weight loss in some patients. It is important to note that Qtern is primarily prescribed for blood sugar management, and any effect on body weight is considered a potential secondary observation.

---

Q: What are the common side effects of Qtern?

A: The most common side effects observed in clinical trials included upper respiratory tract infections, headache, and urinary tract infections. Due to the action of dapagliflozin, patients may experience signs related to volume depletion, such as dizziness. Discussing potential side effects with a healthcare professional is recommended.

How to Store and Dispose of Qtern?

Qtern (dapagliflozin and saxagliptin) must be stored and handled according to official regulatory specifications to maintain its stability and effectiveness.

---

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature between 68 F and 77 F (20 C and 25 C).
Protection	Keep the tablets in the original container, tightly closed, to protect the medication from moisture.
Safety	The product must be stored out of reach of children.
Handling	Tablets must be swallowed whole and should not be crushed, cut, or chewed.

---

️ Disposal Instructions

Dispose of any unused or expired Qtern tablets and waste material in accordance with local regulations for proper management of pharmaceutical waste.